Recurrent mycoplasma pneumoniae infection in a human immunodeficiency virus-positive child

Pediatric Infectious Disease Journal

Volumn 27, Issue 11, 2008, Pages 1037-1038

  Watson, Michael E ^a   Storch, Gregory A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DOXYCYCLINE; IMMUNOGLOBULIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC AGENT;

ARTICLE; B CELL LYMPHOMA; CANCER RECURRENCE; CASE REPORT; CHILD; CLINICAL FEATURE; DYSPNEA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOXEMIA; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT INFECTION; RESPIRATORY DISTRESS; SYMPTOM; THORAX PAIN; AIDS RELATED COMPLEX; FATALITY; ISOLATION AND PURIFICATION; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; SEPSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZITHROMYCIN; CHILD; DOXYCYCLINE; FATAL OUTCOME; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; POLYMERASE CHAIN REACTION; RECURRENCE; SEPSIS; ZIDOVUDINE;

EID: 58149166304     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318178276b     Document Type: Article

References (11)

1. Hammerschlag MR. Mycoplasma pneumoniae infections. Curr Opin Infect Dis. 2001;14:181-186.
2. Park DR, Sherbin VL, Goodman MS, et al. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J Infect Dis. 2001;184:268-277.
3. Lockman S, Hone N, Kenyon TA, et al. Etiology of pulmonary infections in predominantly HIV-infected adults with suspected tuberculosis, Botswana. Int JTuberc Lung Dis. 2003;7:714-723.
4. Shankar EM, Kumarasamy N, Vignesh R, et al. Epidemiological studies on pulmonary pathogens in HIV-positive and-negative subjects with or without community-acquired pneumonia with special emphasis on Mycoplasma pneumoniae. Jpn J Infect Dis. 2007;60:337-341.
5. Pitcher D, Chalker VJ, Sheppard C, George RC, Harrison TG. Real-time detection of Mycoplasma pneumoniaein respiratory samples with an internal processing control. J Med Microbiol. 2006;55:149-155.
6. Hardy RD, Jafri HS, Olsen K, et al. Mycoplasma pneumoniaeinduces chronic respiratory infection, airway hyperreactivity, and pulmonary inflammation: a murine model of infection-associated chronic reactive airway disease. Infect Immun. 2002;70:649-654.
7. Smith CB, Friedewald WT, Chanock RM. Shedding of Mycoplasma pneumoniaeafter tetracycline and erythromycin therapy. NEngl JMed. 1967;276:1172-1175.
8. Dallo SF, Baseman JB. Intracellular DNA replication and long-term survival of pathogenic mycoplasmas. Microb Pathog. 2000;29:301-309.
9. Morozumi M, Iwata S, Hasegawa K, et al. Increased macrolide resistance of Mycoplasma pneumoniaein pediatric patients with communityacquired pneumonia. Antimicrob Agents Chemother. 2008;52:348-350.
10. Morozumi M, Hasegawa K, Kobayashi R, et al. Emergence of macrol-ide-resistant Mycoplasma pneumoniaewith a 23S rRNA gene mutation. Antimicrob Agents Chemother. 2005;49:2302-2306.
11. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005; 106:1538-1543.